Drug development of novel therapeutics is increasing, and a growing number of pharmaceutical and biotech companies are seeking clinical manufacturing partners to meet the demand for complex fill and finish solutions. While the stages of early drug development are challenging, Vetter, a leading global Contract Development and Manufacturing Organization (CDMO) is committed to addressing this challenge. The family-owned company offers comprehensive and expert manufacturing services for clinical trials to support a product’s path to commercialization. A testament to this commitment is evidenced by the success of its Skokie facility located at the Illinois Science + Technology Park, which has already contributed to bringing five new client products to market since it began full operations in 2011. Another four are expected to launch in the next months.
Since the site opened, 240+ customer audits have been successfully completed; the facility has performed over 45 media fills without failure. Vetter Development Service currently runs 80+ projects in phase I and II of clinical development. The US facility has executed 30+ transfers from its early clinical projects to Germany for late-stage development.
“Our clinical manufacturing sites are essential to Vetter’s commercial business pipeline. The Skokie site has demonstrated an impressive track record of success since its opening twelve years ago,” says Dr. Susanne Lemaine, Vice President Vetter Development Services US. “In the last year alone, we acquired more than 10 new customers with promising molecules. Overall, our ongoing investments in clinical filling capabilities are proof of Vetter’s consistent, strategic approach to keeping on track with the market, with a focus on the important drug development needs of our customers.”